Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension

Expert Opinion on Pharmacotherapy

Volumn 18, Issue 18, 2017, Pages 1903-1919

  Kadowaki, Takashi ^a   Muto, Satsuki ^b   Ouchi, Yoshiumi ^b   Shimazaki, Ryutaro ^b   Seino, Yutaka ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Dipeptidyl peptidase 4 inhibitors; elderly patients; insulin; Japanese; saxagliptin; type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SAXAGLIPTIN; SITAGLIPTIN; 1,5-ANHYDROGLUCITOL; ADAMANTANE; ANTIDIABETIC AGENT; DEOXYGLUCOSE; DIPEPTIDE; GLUCAGON; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INFLUENZA; INSULIN TREATMENT; JAPANESE (PEOPLE); KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; JAPAN; MIDDLE AGED; MULTICENTER STUDY; PLACEBO EFFECT;

ADAMANTANE; AGED; BLOOD GLUCOSE; C-PEPTIDE; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; MALE; MIDDLE AGED; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 85031421206     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2017.1379990     Document Type: Article

References (31)

1. Araki E, Haneda M, Kasuga M, et al. New glycemic targets for patients with diabetes from the Japan diabetes society. Diabetol Int. 2016;7(4):327–330.
2. Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes. Committee report: glycemic targets for elderly patients with diabetes. Diabetol Int. 2016;7(4):331–333.
3. Seino Y, Kuwata H, Yabe D., Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Invest. 2016;7(Suppl1):102–109.
4. Deacon CF, Holst JJ., Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–2058.
5. Wani JH, John-Kalarickal J, Fonseca VA. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin. 2008;26(4):639–648.
6. Strain WD, Lukashevich V, Kothny W, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382(9890):409–416.
7. Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902):1413–1423.
8. Umezawa S, Kubota A, Maeda H, et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15:34.
9. Hirose T, Suzuki M, Tsumiyama I. Efficacy and safety of vildagliptin as an add-on to insulin with or without metformin in Japanese patients with type 2 diabetes mellitus: a 12-week, double-blind, randomized study. Diabetes Ther. 2015;6:559–571.
10. Kadowaki T, Tajima N, Odawara M, et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int. 2013;4(3):160–172.
11. Kaku K, Mori M, Kanoo T, et al. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother. 2014;15(15):2121–2130.
12. Katsuno T, Ikeda H, Namba M. Medium-term effect of add-on therapy with the DPP-4 inhibitor, sitagliptin, in insulin-treated Japanese patients with type 2 diabetes mellitus. Diabetes Ther. 2016;7:309–320.
13. Kaku K, Honda D, Tsubamoto Y, et al. Efficacy and safety of anagliptin add to insulin therapy in Japanese patients with type 2 diabetes: a multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an open-label, long-term extension. Jpn Pharmacol Ther. 2015;43(12):1663–1686.
14. Tajiri Y, Kawano S, Hirao S, et al. Adding of sitagliptin on insulin therapy effectively and safely reduces a hemoglobin A1c level and glucose fluctuation in Japanese patients with type 2 diabetes. Int Sch Res Notices. 2014;2014:639489.
15. Takai M, Ishikawa M, Maeda H, et al. Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study. Diabetes Res Clin Pract. 2014;103:e30–3.
16. Kadowaki T, Kondo K, Sasaki N, et al. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother. 2017;18:1291–1300.
17. Konya H, Yano Y, Matsutani S, et al. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Ther Clin Risk Manag. 2014;10:547–558.
18. Kadowaki T. Effcacy and safety of a novel DPP-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus — the results of clinical trials in Japan. Jpn Pharmacol Ther. 2013;41(8):803–815.
19. Seino Y. Efficacy and safety of saxagliptin in Japanese patients with type 2 diabetes — two multi-centre, randomized, double-blind, placebo-controlled studies. Jpn Pharmacol Ther. 2014;42(7):503–518.
20. Seino Y. Efficacy and safety of long-term saxagliptin monotherapy and add-on therapy in Japanese patients with type 2 diabetes. Jpn Pharmacol Ther. 2014;42:519–534.
21. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513–523.
22. Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig. 2013;33(10):707–717.
23. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:376–386.
24. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411.
25. Frederich R, McNeill R, Berglind N, et al. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012;4:36.
26. Goto Y, Kikuchi H. Application of the M-value, an index of blood sugar control, for the true blood sugar value. J Japan Diabetes Soc. 1972;15(5):319–323.
27. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed. 1996;50(3):253–264.
28. Leibowitz G, Cahn A, Bhatt DL, et al. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. Diabetes Obes Metab. 2015;17(5):487–494.
29. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–1239.
30. Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13(6):523–532.
31. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet. 2011;50(4):253–265.